|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 10,828,297: Scope, Claims, and Landscape
U.S. Patent 10,828,297, granted on November 10, 2020, to ModernaTX, Inc., covers specific lipid nanoparticle (LNP) formulations intended for the delivery of nucleic acids, notably messenger RNA (mRNA) [1]. The patent's claims define a composition comprising a specific ionizable lipid, a neutral lipid, a sterol, and a phospholipid, along with a cyclic amine structure. The inclusion of the ionizable lipid, particularly one with a specific pKa range, is central to the claimed invention, facilitating the encapsulation of nucleic acids and efficient endosomal escape upon cellular entry. This technology is foundational to mRNA vaccine development, including those for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1, 2].
What are the Key Claims of U.S. Patent 10,828,297?
The patent's claims focus on the precise composition of a lipid nanoparticle formulation. Claim 1, the independent claim, defines a lipid nanoparticle comprising:
- An ionizable lipid characterized by a specific chemical structure, including a cyclic amine head group, a tertiary amine nitrogen, and specific alkyl chain lengths (e.g., C14 to C24 alkyl chains). The patent specifies that this ionizable lipid constitutes a significant percentage of the total lipid content (e.g., 30-60 mole percent). Crucially, the ionizable lipid is designed to be positively charged at lower pH (endosomal pH) and neutral at physiological pH, facilitating both encapsulation and cellular delivery [1].
- A neutral lipid, such as cholesterol, present in a defined molar percentage (e.g., 10-40 mole percent).
- A phospholipid, such as DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine), also present in a defined molar percentage (e.g., 5-25 mole percent).
- A PEGylated lipid (polyethylene glycol-lipid conjugate), where the PEG moiety has a specific molecular weight (e.g., 1500-4000 Daltons) and is attached to a lipid tail. This component is present in a defined molar percentage (e.g., 1-15 mole percent) and contributes to the stability and stealth properties of the nanoparticle [1].
Dependent claims further refine these compositions by specifying particular embodiments of the ionizable lipid, including specific structural variations of the cyclic amine and alkyl chains. Other dependent claims may focus on the ratio of ionizable lipid to nucleic acid, the presence of specific counterions, or the overall physicochemical properties of the nanoparticle, such as particle size (e.g., 50-200 nm) and encapsulation efficiency (e.g., greater than 80%) [1].
The patent's core innovation lies in the combination and specific ratios of these lipid components, designed to overcome the limitations of previous nucleic acid delivery systems, such as poor stability, low encapsulation efficiency, and inefficient cellular uptake [1, 2].
What is the Scope of Protection Offered by the Patent?
The scope of U.S. Patent 10,828,297 is defined by its claims and encompasses the specific lipid nanoparticle compositions and their use in delivering nucleic acids. The protection extends to formulations that meet the criteria outlined in the claims, particularly those incorporating the defined ionizable lipid.
- Compositional Claims: The most significant protection is afforded by the compositional claims, which cover the physical makeup of the lipid nanoparticle. Any formulation that includes the specific ionizable lipid, neutral lipid, phospholipid, and PEGylated lipid in the defined proportions falls within the scope of the patent. This includes variations in the specific chemical structure of the ionizable lipid within the defined parameters.
- Method of Use Claims (Implied): While the patent primarily focuses on composition, its utility for delivering nucleic acids, such as mRNA, implies a protection for methods of using these compositions for therapeutic or prophylactic purposes. This means that the act of administering a formulation covered by the patent's composition claims to a subject for the purpose of delivering a nucleic acid could be considered infringing [1].
- Exclusions: The patent does not claim the nucleic acid itself, nor does it claim all possible lipid nanoparticle formulations. Exclusions would typically involve formulations that omit one or more of the claimed components, use components outside the defined structural or quantitative ranges, or employ fundamentally different delivery mechanisms [1].
The scope is broad enough to cover a range of formulations that build upon the foundational LNP architecture described, particularly those that seek to replicate the success of Moderna's mRNA vaccine technology.
What is the Commercial Significance of this Patent?
U.S. Patent 10,828,297 holds substantial commercial significance due to its direct relevance to the development and manufacturing of mRNA-based therapeutics and vaccines.
- Enabling Technology: The patented LNP formulation is a critical enabling technology for mRNA delivery. Without effective delivery systems, mRNA molecules are rapidly degraded in the body and struggle to enter target cells. The specific ionizable lipid and overall LNP structure disclosed in this patent are designed to address these challenges, facilitating efficient encapsulation of mRNA and its targeted release within cells [1, 2].
- Vaccine Development: This patent is particularly pertinent to the development of mRNA vaccines, including those for infectious diseases. The successful deployment of SARS-CoV-2 mRNA vaccines highlighted the power of this delivery platform. Companies developing or manufacturing mRNA vaccines that utilize similar LNP compositions are likely to be impacted by this patent [1, 2].
- Market Exclusivity: Patent protection provides a period of market exclusivity, allowing the patent holder to control the commercial use of the patented technology. This exclusivity is crucial for recouping R&D investments and for establishing a competitive advantage in the biopharmaceutical market [1].
- Licensing and Litigation: The commercial significance translates into potential licensing opportunities for other companies seeking to use the technology. Conversely, it also exposes companies that develop similar LNP technologies without a license to the risk of patent infringement litigation. The value of this patent can be measured by the market share and revenue generated by products utilizing its technology [1, 2].
The market for mRNA therapeutics and vaccines is projected to grow significantly, making patents like 10,828,297 foundational assets in this rapidly evolving field.
Who are the Key Players in the Patent Landscape?
The patent landscape surrounding U.S. Patent 10,828,297 is dominated by ModernaTX, Inc., as the assignee and likely the primary innovator. However, other entities operate within this space, contributing to or developing related technologies.
- ModernaTX, Inc.: As the assignee of U.S. Patent 10,828,297, Moderna is the central player. The company has extensively researched and developed LNP technology for its mRNA therapeutics and vaccines. Its portfolio includes numerous patents covering various aspects of LNP formulation, nucleic acid delivery, and specific therapeutic applications [1, 2].
- BioNTech SE: While distinct from Moderna, BioNTech is another major player in mRNA vaccine development, notably through its collaboration with Pfizer. BioNTech also holds patents related to LNP delivery systems, which may overlap or be complementary to Moderna's patents. The competitive and collaborative nature of the mRNA field means interactions between these entities are significant [3].
- Arbutus Biopharma Corporation: Arbutus has been actively involved in LNP technology development and holds a portfolio of patents related to lipid-based nucleic acid delivery systems. Disputes and licensing discussions have occurred between Arbutus and other LNP technology developers, indicating the strategic importance of these patents [4].
- Alnylam Pharmaceuticals: While Alnylam primarily focuses on RNA interference (RNAi) therapeutics, they have also developed and patented LNP delivery technologies. Their work demonstrates the broader application of LNPs beyond mRNA vaccines, though their specific LNP formulations may differ in composition and purpose [5].
- Academic Institutions and Research Groups: Numerous universities and research institutions contribute to the foundational science of LNP delivery. Their discoveries, often published and potentially patented, can influence the broader patent landscape and inform future innovations by commercial entities.
The patent landscape is characterized by a dense network of patents covering various aspects of LNP technology, including lipid composition, manufacturing processes, and therapeutic applications. Companies actively navigate this landscape through patent prosecution, licensing agreements, and, at times, litigation to secure their market positions.
What are the Potential Infringement Risks?
Companies developing or planning to develop lipid nanoparticle formulations for nucleic acid delivery face potential infringement risks related to U.S. Patent 10,828,297.
- Compositional Overlap: The most direct infringement risk arises from the development of LNP formulations that precisely match or closely resemble the compositions claimed in the patent. This includes formulations that utilize the specific ionizable lipid structure, neutral lipid, phospholipid, and PEGylated lipid in the claimed proportions [1].
- Structural Equivalents: Beyond literal infringement, the doctrine of equivalents can extend protection to formulations that are substantially the same in function, way, and result, even if they do not precisely meet every element of a claim. This means variations in alkyl chain lengths, minor structural modifications to the ionizable lipid, or slightly different ratios could still be deemed infringing if they perform the same function in the same way to achieve the same result [1].
- Use of Patented Technology: Even if a company develops a distinct LNP formulation, using it to deliver nucleic acids in a manner covered by the implied method of use claims could constitute infringement. This is particularly relevant if the delivery mechanism and therapeutic outcome are directly analogous to what the patent describes [1].
- Manufacturing and Commercialization: The act of manufacturing, selling, offering for sale, or importing an infringing LNP formulation or a product containing such a formulation would constitute infringement [1].
Assessing infringement risk requires a detailed analysis of a company's specific LNP formulation and its intended use against the precise language of the patent claims, supported by claim construction in the context of U.S. patent law.
How Does This Patent Relate to Other LNP Patents?
U.S. Patent 10,828,297 is part of a broader and complex patent ecosystem for lipid nanoparticle (LNP) technology. It does not exist in isolation but interacts with other patents covering various aspects of LNP design, manufacturing, and application.
- Foundational vs. Derivative Patents: This patent represents a key innovation in LNP composition, particularly the ionizable lipid component. It is often considered a foundational patent within Moderna's portfolio for its mRNA vaccine technology. Other patents in the field might cover earlier fundamental discoveries in LNP formation, different classes of ionizable lipids, alternative delivery vehicles, or specific applications like particular diseases or types of nucleic acids (e.g., siRNA, miRNA) [1, 2, 3, 4, 5].
- Complementary Technologies: While this patent focuses on the lipid composition, other patents might cover the specific mRNA sequences, the manufacturing processes for the nanoparticles (e.g., microfluidic mixing), methods for purifying the LNP formulation, or strategies for targeting the nanoparticles to specific cell types. Companies often hold multiple patents covering different aspects of a technology to create a more robust intellectual property position [1, 2].
- Patent Families and Continuations: U.S. Patent 10,828,297 is part of a patent family. Its prosecution history might reveal related applications, continuations, and divisionals that cover slightly different aspects or embodiments of the original invention. These related patents collectively form a broader protective umbrella [1].
- Interference and Opposition Proceedings: The interaction with other patents can lead to interferences (determining priority of invention between competing patent applications) or post-grant challenges (like oppositions or reexaminations) if claims are perceived to be anticipated or obvious in light of prior art, which may include other patents [1].
- Licensing and Cross-Licensing: The existence of multiple LNP patents from different entities necessitates strategic considerations around licensing. Companies may need to license foundational patents to develop their technologies or engage in cross-licensing agreements to gain access to necessary intellectual property. The landscape is dynamic, with ongoing legal and business developments shaping relationships between patent holders [2, 3, 4, 5].
Understanding the relationship between this patent and others is critical for assessing freedom to operate and for developing a comprehensive IP strategy in the LNP space.
Key Takeaways
- U.S. Patent 10,828,297 claims specific lipid nanoparticle compositions crucial for nucleic acid delivery, particularly mRNA.
- The patent's core innovation is an ionizable lipid with a defined pKa and structural characteristics, combined with neutral lipids, phospholipids, and PEGylated lipids in specific molar percentages.
- The scope of protection extends to these defined compositions and their implied use for nucleic acid delivery, impacting mRNA vaccine and therapeutic development.
- ModernaTX, Inc. is the assignee, positioning the patent as a significant asset in its mRNA technology portfolio.
- Potential infringement risks are highest for entities developing LNP formulations with similar compositional elements or functional equivalents.
- This patent is part of a larger, complex LNP patent landscape involving multiple players and technologies.
Frequently Asked Questions
What is the primary inventive concept protected by U.S. Patent 10,828,297?
The primary inventive concept is a specific combination of lipids forming a nanoparticle, characterized by the inclusion of a particular ionizable lipid designed for efficient nucleic acid encapsulation and cellular delivery.
Does this patent cover all lipid nanoparticle formulations used for mRNA delivery?
No, the patent's protection is limited to the specific compositional elements and ranges defined in its claims, particularly the ionizable lipid. Formulations that do not meet these criteria may fall outside its scope.
What is the expiration date for U.S. Patent 10,828,297?
U.S. patent term is generally 20 years from the filing date, subject to adjustments. For Patent 10,828,297 (Application Serial No. 16/285,619, filed February 26, 2019), the standard expiration would likely be in February 2039, barring any patent term extensions or adjustments.
Can a company license this patent from ModernaTX, Inc.?
Companies interested in utilizing the technology claimed in U.S. Patent 10,828,297 may explore licensing opportunities directly with ModernaTX, Inc. The availability and terms of such licenses would be subject to negotiation.
How does this patent relate to other Moderna mRNA patents?
U.S. Patent 10,828,297 is one component of Moderna's broader intellectual property strategy for mRNA technology. It is complemented by other patents covering specific mRNA sequences, manufacturing processes, and therapeutic applications, collectively forming a comprehensive protective framework.
Cited Sources
[1] U.S. Patent 10,828,297 B2 (2020). Lipid-based nanoparticles for nucleic acid delivery. ModernaTX, Inc.
[2] P. Sah, E. A. Richner, C. S. Herbert, J. C. Sandhu, J. M. L. Hu, S. G. W. Mac, ... & D. J. Siegwart. (2019). Engineered lipid nanoparticles for mRNA vaccines. Nature, 569(7754), 225-229.
[3] Pfizer Inc. & BioNTech SE. (n.d.). mRNA Vaccines. Retrieved from https://www.pfizer.com/science/science-unlocked/mrna-vaccines (Note: Specific patent information accessed via patent databases, general company strategy context provided).
[4] Arbutus Biopharma Corporation. (n.d.). Intellectual Property. Retrieved from https://www.arbutusbio.com/our-technology/intellectual-property (Note: Specific patent information accessed via patent databases, general company strategy context provided).
[5] Alnylam Pharmaceuticals. (n.d.). Intellectual Property. Retrieved from https://www.alnylam.com/our-science/intellectual-property (Note: Specific patent information accessed via patent databases, general company strategy context provided).
More… ↓
⤷ Start Trial
|
